Curis, Inc. (NASDAQ:CRIS)’s stock price fell 14.7% on Friday . The stock traded as low as $1.41 and last traded at $1.57, 2,287,334 shares changed hands during trading. An increase of 625% from the average session volume of 315,605 shares. The stock had previously closed at $1.84.

Separately, ValuEngine lowered shares of Curis from a “hold” rating to a “sell” rating in a research note on Tuesday, December 3rd.

The business’s fifty day moving average is $1.83 and its two-hundred day moving average is $1.92.

Curis (NASDAQ:CRIS) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.19) EPS for the quarter. The business had revenue of $2.86 million for the quarter.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Sunbelt Securities Inc. bought a new position in Curis in the third quarter worth approximately $27,000. Morgan Stanley raised its position in Curis by 155.6% during the 2nd quarter. Morgan Stanley now owns 19,564 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 11,911 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of Curis in the 2nd quarter worth $40,000. Cetera Advisor Networks LLC purchased a new stake in shares of Curis in the 2nd quarter worth $42,000. Finally, BB&T Securities LLC lifted its holdings in shares of Curis by 131.6% in the 3rd quarter. BB&T Securities LLC now owns 43,994 shares of the biotechnology company’s stock worth $99,000 after buying an additional 25,000 shares during the period. Hedge funds and other institutional investors own 26.32% of the company’s stock.

About Curis (NASDAQ:CRIS)

Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.

Further Reading: Risk Tolerance

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.